 B. Riley restated their buy rating on shares of DURECT NASDAQ:DRRX in a research note issued to investors on Monday morning, TipRanks reports. B. Riley currently has a 5.00 price objective on the specialty pharmaceutical companys stock. DRRX has been the subject of several other research reports. ValuEngine raised DURECT from a hold rating to ... 